0001193125-22-163800.txt : 20220531 0001193125-22-163800.hdr.sgml : 20220531 20220531150100 ACCESSION NUMBER: 0001193125-22-163800 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20220524 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20220531 DATE AS OF CHANGE: 20220531 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC CENTRAL INDEX KEY: 0001048477 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 680397820 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-26727 FILM NUMBER: 22982727 BUSINESS ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 BUSINESS PHONE: 4155066700 MAIL ADDRESS: STREET 1: 105 DIGITAL DRIVE CITY: NOVATO STATE: CA ZIP: 94949 8-K 1 d356349d8k.htm 8-K 8-K
BIOMARIN PHARMACEUTICAL INC false 0001048477 0001048477 2022-05-24 2022-05-24

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 24, 2022

 

 

BioMarin Pharmaceutical Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   000-26727   68-0397820

(State or Other Jurisdiction

of Incorporation)

  (Commission
File Number)
 

(IRS Employer

Identification No.)

 

770 Lindaro Street, San Rafael, California   94901
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 506-6700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

 

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.001 par value   BMRN   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 24, 2022, BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”). A total of 184,898,129 shares of common stock were entitled to vote as of March 28, 2022, the record date for the Annual Meeting. There were 157,248,760 shares of common stock present in person or represented by proxy at the Annual Meeting at which the stockholders were asked to vote on three proposals, each of which is described in more detail in BioMarin’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 12, 2022 (the “Proxy Statement”). Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal.

Proposal No. 1: Election of Directors

 

Directors Elected

   Vote For    Withheld    Broker
Non-Votes

Mark J. Alles

   134,357,621    12,349,973    10,541,166

Elizabeth McKee Anderson

   138,852,305    7,855,289    10,541,166

Jean-Jacques Bienaimé

   133,104,668    13,602,926    10,541,166

Willard Dere, M.D.

   141,281,714    5,425,880    10,541,166

Elaine J. Heron, Ph.D.

   129,036,966    17,670,628    10,541,166

Maykin Ho

   146,007,145    700,449    10,541,166

Robert J. Hombach

   141,119,244    5,588,350    10,541,166

V. Bryan Lawlis, Ph.D.

   140,266,110    6,441,484    10,541,166

Richard A. Meier

   140,377,231    6,330,363    10,541,166

David E.I. Pyott, M.D. (Hon.)

   139,737,870    6,969,724    10,541,166

Dennis J. Slamon, M.D., Ph.D.

   143,191,445    3,516,149    10,541,166

Based on the votes set forth above, BioMarin’s stockholders elected each of the eleven nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director’s death, resignation or removal.

Proposal No. 2: Ratification of the Selection of Independent Registered Public Accounting Firm

The ratification of the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the fiscal year ending December 31, 2022, as set forth in the Proxy Statement, received the following votes:

 

For

 

Against

 

Abstain

153,373,736   3,776,965   98,059

Based on the votes set forth above, BioMarin’s stockholders ratified the selection of KPMG LLP as BioMarin’s independent registered public accounting firm to serve for the year ending December 31, 2022.

Proposal No. 3: Advisory Vote on the Compensation of Named Executive Officers

The advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes:

 

For

 

Against

 

Abstain

 

Broker
Non-Votes

79,494,727   64,157,192   3,055,675   10,541,166

Based on the votes set forth above, BioMarin’s stockholders approved, on an advisory basis, the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

   

BioMarin Pharmaceutical Inc.,

a Delaware corporation

Date: May 31, 2022     By:  

/s/ G. Eric Davis

     

G. Eric Davis

Executive Vice President, Chief Legal Officer

EX-101.SCH 2 bmrn-20220524.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 bmrn-20220524_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 bmrn-20220524_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information
May 24, 2022
Cover [Abstract]  
Entity Registrant Name BIOMARIN PHARMACEUTICAL INC
Amendment Flag false
Entity Central Index Key 0001048477
Document Type 8-K
Document Period End Date May 24, 2022
Entity Incorporation State Country Code DE
Entity File Number 000-26727
Entity Tax Identification Number 68-0397820
Entity Address, Address Line One 770 Lindaro Street
Entity Address, City or Town San Rafael
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94901
City Area Code (415)
Local Phone Number 506-6700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value
Trading Symbol BMRN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 6 d356349d8k_htm.xml IDEA: XBRL DOCUMENT 0001048477 2022-05-24 2022-05-24 BIOMARIN PHARMACEUTICAL INC false 0001048477 8-K 2022-05-24 DE 000-26727 68-0397820 770 Lindaro Street San Rafael CA 94901 (415) 506-6700 false false false false Common Stock, $0.001 par value BMRN NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d356349d8k.htm bmrn-20220524.xsd bmrn-20220524_lab.xml bmrn-20220524_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d356349d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d356349d8k.htm" ] }, "labelLink": { "local": [ "bmrn-20220524_lab.xml" ] }, "presentationLink": { "local": [ "bmrn-20220524_pre.xml" ] }, "schema": { "local": [ "bmrn-20220524.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bmrn", "nsuri": "http://www.biomarin.com/20220524", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d356349d8k.htm", "contextRef": "duration_2022-05-24_to_2022-05-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d356349d8k.htm", "contextRef": "duration_2022-05-24_to_2022-05-24", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.biomarin.com//20220524/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 14 0001193125-22-163800-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-22-163800-xbrl.zip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end